Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

NexLife vs Royal Medical Center

NexLife
Graded #147

Higher grade

vs+19.1
Royal Medical Center
Graded #492

Lower grade

The verdict

NexLife takes it — 68.5/100 to 49.4/100.

NexLife grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. NexLife is a LegitScript-certified telehealth platform offering compounded semaglutide (from $145/mo) and compounded tirzepatide (from $186/mo).

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueNexLife +48
70
22
Dose & formulationNexLife +22
64
42
Clinical oversightNexLife +27
89
62
Labs & monitoringRoyal Medical Center +33
53
86
FulfillmentNexLife +19
67
48
Contract termsEven
55
55
NexLife · left barRoyal Medical Center · right bar

The numbers

MetricNexLifeRoyal Medical Center
WeighScore68.5/10049.4/100
GradeCC
Scorecard rank#147#492
Semaglutide$165/mo (compounded)Not disclosed
Tirzepatide$215/mo (compounded)$450/mo (2.5 mg dose, compounded)
CoverageCoverage not publishedCoverage not published
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyInjection only
NexLife

Graded #147 · C

Strengths

  • LegitScript certified platform
  • Works exclusively with LegitScript-certified, NABP-accredited pharmacies — strongest pharmacy trust signal in the dataset
  • Both semaglutide and tirzepatide at competitive pricing
  • Semaglutide from $145/mo on the 12-month plan ($165/mo month-to-month) - among the lowest in the dataset

Where it loses points

  • State availability not publicly disclosed
  • Compounded only — no brand-name options
  • Also covers hormone optimization and longevity
  • Lowest advertised rates ($145 sema / $186 tirz) require a 12-month plan commitment
Royal Medical Center

Graded #492 · C

Strengths

  • Physician founder Dr. Dagoberto Rodriguez, MD — Emory residency, former Coral Springs Medical Center chairman, U Miami faculty
  • Tirzepatide pricing fully itemized by dose tier ($450 / $650 / $800 / $1,100) — more transparent than 'starting at' floors
  • All-inclusive pricing bundles medication, supplies, injections, lab monitoring, and physician follow-ups
  • Broad catalog (HRT, TRT, peptides, ED, hair, vitamins) reflects an established multi-program clinic
  • Florida physician with 30+ years of practice — a strong physician-led care signal

Where it loses points

  • Operating legal entity not disclosed — only the 'Royal Medical Center' brand surfaced
  • Pharmacy partner not named — buyers can't verify licensure or 503A/503B status
  • No LegitScript badge displayed
  • States served not enumerated — site says 'nationwide' with no state list
  • Headline 'starting at $116/mo' conflicts with the actual $450/mo tirzepatide floor

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard